Merely a minute into his prepared remarks during Jazz Pharmaceuticals ... its debt since closing the GW deal, as well, Johnson pointed out. A de-levered balance sheet and continued strong ...

At this time, I would like to welcome everyone to the Jazz Pharmaceuticals Fourth Quarter ... as we assess opportunities to maximize long-term shareholder value through corporate development.

If we add up Rockdale's 700MW of immediately available power, the company has 1.1 GW available ... its balance sheet. A 50% selloff in Bitcoin's price could lead to a loss in long-term assets ...

To narrow down the investment universe, Sun and his team focus on five themes: Green China (environmental protection and renewable energy), Healthy China (healthcare and pharmaceuticals ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands ...

Meanwhile, the three-year fixed-rate note garnered US$1.4 billion in interest from 102 accounts, according to the term sheet. Asian investors accounted for nearly half of the offers, with interest ...

In a recent SEC filing, Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) disclosed its unaudited consolidated balance sheet as of January 31, 2025. The Edison, New Jersey-based pharmaceutical company ...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ sits at a Zacks Rank #3 (Hold), holds a Value Style Score of A ...